Using artificial intelligence to identify patient characteristics associated with rapid fibrosis progression in NASH: a retrospective cohort study
Barriers to and opportunities for improved MASLD/MASH education: a qualitative discussion with medical training program leaders
When to Intervene? Onset and Timing of Obesity-related Metabolic Derangements After Liver Transplant
Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic MASLD
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MIRICORILANT IN ADULT PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS/METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (NASH/MASH)
Is it fatty liver or fatty pancreas have more cvs affection and why
The Effects of a Combined Exercise Interventionon Gut Microbiomes and Systemic InflammatoryBiomarkers in MASLD Patients: A Study Protocol
Next Generation HepQuant Tests for the Clinic and Clinical Trials: Within Individual Reproducibility and Diagnostic Performance for Large Esophageal Varices
The Disease Severity Index from HepQuant DuO and Likelihood for Large Esophageal Varices in the SHUNT V Study
Stratifying Disease Severity and Predicting Risk for Clinical Decompensation in Primary Sclerosing Cholangitis: Results with Next Generation HepQuant Tests
The NEXT GENERATION HepQuant Tests Measure Reduction in Risk for Clinical Events in Compensated NASH Cirrhosis Subjects Treated with Resmetirom
Comparison of costs and referral rates of non-invasive testing strategies for metabolic dysfunction-associated steatohepatitis (MASH) in a Veteran population
Imaging in Chronic Liver Disease: A Comparative Analysis Using Magnetic Resonance Elastography and Multiparametric Magnetic Resonance Imaging
THE PERFORMANCE OF VELACUR AGAINST LIVER BIOPSY FOR ASSESSING FIBROSIS AND STEATOSIS
FIBROSIS DISTRIBUTION IN LEAN VERSUS OBESE NASH-CIRRHOSIS PATIENTS USING SHG/TPE MICROSCOPY
Non-invasive tests as a prediction tool to assess MASH resolution score
Performance of novel collagen turnover biomarkers in comparison to FIB-4 to detect increased liver stiffness in MASLD
LIVERFASt (L-FAST) identifies advanced (F3F4, AF) and clinically significant fibrosis (F2-F4, CSF) especially well with Fibroscan in MASLD patients (pts) from a tertiary hepatology center.
Characterizing the management of patients with NASH (with versus without cirrhosis) in real-world clinical practice –Low utilization of gastroenterology and hepatology specialty care
Characterizing the real-world clinical outcomes of patients with NASH without cirrhosis versus with cirrhosis
A longitudinal assessment of cardiovascular risk for NASH/MASH patients enrolled in TARGET-NASH
Deploying a Consensus Metabolic Dysfunction-Associated Steatohepatitis (MASH) Care Pathway and Educational Pilot in Three U.S. Health Systems
Comparing cardiovascular and infection complications in liver transplant patients with NASH vs other indications
Semaglutide and lanifibranor differentially alter MASH and liver fibrosis in diet-induced obese hamsters with or without free access to alcohol
Targeting EF-hand domain family member D1 (EFHD1) in liver disease
Preclinical characterization of bi-functional NK-aHSC engager for liver fibrosis
Lysophosphatidic acid receptor 1 antagonist (EPGN2154) improves murine MASH.
Lanifibranor Reverses Hepatic and Peripheral Insulin Resistance, Improves Lipid and Glucose Metabolism in Patients with Type 2 Diabetes (T2D) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
ORAL αvβ6/αvβ1 INTEGRIN INHIBITION IN PRIMARY SCLEROSING CHOLANGITIS: 12-WEEK INTERIM SAFETY AND EFFICACY ANALYSIS OF INTEGRIS-PSC, A PHASE 2A TRIAL OF BEXOTEGRAST
Inhibition of integrin αVβ1 attenuates profibrogenic gene expression by myofibroblasts in fibrotic human liver explants
Postprandial plasma proteomics in metabolic dysfunction-associated steatotic liver disease
The crosslinked type III collagen biomarker, CTX III, reflects fibrosis resolution and is related to intervention and survival in chronic liver disease
Higher FIB-4 is associated with higher clinical and economic burden of CV events in non-cirrhotic NASH
Enhancing ASCVD Risk Prediction in NASH/NAFLD Patients
Low Immunogenicity Rates in Phenotypic MASH Patients Treated for 12 Weeks With Once-monthly and Bi-weekly Subcutaneous Dosing of BOS-580
The small molecule competitive inhibitor of ATP citrate lyase, EVT0185, reverses liver fibrosis in preclinical mouse models by targeting hepatic stellate cells
Improvements in Liver Fibroinflammation(as assessed by Corrected T1 [cT1]) with HTD1801 (Berberine Ursodeoxycholate) Treatment in Patients with Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus
PLN-1474, AN ORAL, SELECTIVE αvβ1 INTEGRIN INHIBITOR, IS WELL TOLERATED IN HEALTHY VOLUNTEERS
HEPATIC FUNCTIONAL IMPROVEMENT DETECTED BY HEPQUANT DUO WITHIN 120 DAYS OF TREATMENT WITH RENCOFILSTAT (RCF) IN MASH SUBJECTS WITH ≥ F3 FIBROSIS
Miricorilant reduced liver fat and cardiometabolic disease markers in a phase 1b, open-label dose-finding study in patients with non-alcoholic steatohepatitis (NASH)
Pemvidutide-Induced Liver Fat Reduction in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease Correlates with Improvements in Non-Invasive Markers of Inflammation and Fibrosis: Results of a 24-Week Multicenter, Randomized, Double-blind, Placebo-controlled Trial
All Copyright © Reserved by MASH-TAG
Internet Explorer is not supported by this site.
Please consider using Google Chrome or Microsoft Edge instead.
